REPL Replimune Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REPL

Price (delayed)

$10.36

Market cap

$636.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.24

Enterprise value

$635.97M

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary ...

Highlights
Replimune Group's quick ratio has decreased by 39% YoY and by 14% from the previous quarter
The company's equity fell by 33% YoY and by 11% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.replimune.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of REPL
Market
Shares outstanding
61.42M
Market cap
$636.26M
Enterprise value
$635.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$208.73M
EBITDA
-$206.07M
Free cash flow
-$191.13M
Per share
EPS
-$3.24
Free cash flow per share
-$2.87
Book value per share
$6.1
Revenue per share
$0
TBVPS
$7.33
Balance sheet
Total assets
$487.72M
Total liabilities
$113.21M
Debt
$75.87M
Equity
$374.51M
Working capital
$393.23M
Liquidity
Debt to equity
0.2
Current ratio
10.72
Quick ratio
10.57
Net debt/EBITDA
0
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-39.5%
Return on equity
-48.6%
Return on invested capital
-42.9%
Return on capital employed
-46.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
-1.15%
1 week
4.75%
1 month
18.94%
1 year
-50%
YTD
22.89%
QTD
15.11%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$234.77M
Net income
-$215.79M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 33% year-on-year and by 2.5% since the previous quarter
The net income has contracted by 24% YoY and by 2.8% from the previous quarter

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
1.7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 8% YoY and by 2.5% QoQ
The company's equity fell by 33% YoY and by 11% QoQ
REPL's price to book (P/B) is 31% lower than its 5-year quarterly average of 2.5 and 4.4% lower than its last 4 quarters average of 1.8

Efficiency

How efficient is Replimune Group business performance
REPL's ROE is down by 36% YoY and by 13% QoQ
Replimune Group's return on assets has decreased by 26% YoY and by 10% QoQ
Replimune Group's return on invested capital has decreased by 10% YoY and by 7% QoQ

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
Replimune Group's quick ratio has decreased by 39% YoY and by 14% from the previous quarter
REPL's current ratio is down by 39% YoY and by 14% QoQ
Replimune Group's debt is 80% less than its equity
The debt to equity has surged by 82% year-on-year and by 11% since the previous quarter
The company's equity fell by 33% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.